Proteor to Expand Lower Limb Prosthetics Portfolio Through Its Acquisition of Freedom Innovations Assets
9.10.2020 21:58:00 EEST | Business Wire | Press release
Proteor USA, LLC, a wholly owned subsidiary of the France based, Proteor Group, has signed an agreement with Ottobock to acquire a significant portion of the lower limb prosthetics portfolio of Freedom Innovations which demonstrates Proteor’s continued commitment and investment in the worldwide prosthetic industry. The agreement was reached by Proteor and Ottobock at the end of September 2020 and the proposed transaction is anticipated to close by the end of 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005566/en/
Under the agreement, Proteor will expand substantially its lower limb prosthetics portfolio and acquire a range of Freedom Innovations’ flagship products, including the Plié3 microprocessor knee, the Kinnex and Kinterra ankles, and the Agilix, Highlander, Dynadapt, Sierra and Pacifica feet products.
Both Proteor and Freedom Innovations share a similar mission to increase the independence and well-being of people who use their products by offering innovative, high-performance solutions that deliver security, stability, and comfort for a reasonable price. Through the acquisition of a significant portion of Freedom Innovations, Proteor is eager to combine the teams in the United States and Europe and expand globally, thereby providing a clear choice to prosthetists and their patients for enhanced outcomes.
“We strongly believe in the long-term benefits of this move for the people we serve around the world. By combining the expertise of our teams in the US and Europe, the momentum we generate will continue to build Proteor’s presence within the O&P community,” said Edouard Archambeaud, COO and member of the Managing Board of Proteor.
Matthew Swiggum, President and CEO of Proteor USA states, “We are dedicated to providing inventive, dependable products to the orthotic and prosthetic community that offer increased independence with an outstanding product portfolio. Working with the passionate and skilled team at Freedom Innovations is a pleasure we’re all looking forward to.”
For Proteor, the proposed transaction will reinforce its positioning and growth strategy worldwide, while creating synergies within innovation platforms, significant continuous R&D investment, and a focus on mechatronic lower limb solutions. This proposed transaction will further build upon Proteor’s presence in the United States lower limb prosthetics market, already strengthened by Proteor’s prior acquisition of Ability Dynamics’ RUSH Foot portfolio, which further illustrates Proteor’s commitment to its markets worldwide.
The terms of the proposed transaction between Proteor and Ottobock remain subject to the final approval of the Commissioners of the U.S. Federal Trade Commission (FTC) and are meant to satisfy Ottobock’s obligations under the Order from the FTC to divest certain assets from the U.S. company Freedom Innovations. Once approval from the FTC is obtained, Proteor USA will integrate a significant number of Freedom Innovations team members in manufacturing, sales, marketing, R&D and clinical from Gunnison, Utah; Irvine, California; and Germany.
About Proteor
Proteor, an independent family-company, was established 105 years ago with its headquarters in Dijon, France. Proteor operates in the O&P market with three key areas of activities: software’s, components and custom-made devices. Thanks to continuous investments in innovation, many medical and scientific partnerships, and day to day cooperation with CPOs, Proteor enjoys a recognized expertise all over the O&P community.
For additional information visit http://proteorusa.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005566/en/
Contact information
Media:
Sophie Desbois
Sophie.desbois@proteor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 15:23:00 EEST | Press release
The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in northern Finland.” A year of major exhibitions across the city Oulu’s exhibition programme extends beyond traditional museum spaces. Art appears in unexpected places such as a shopping centre, the city hall, a cathedral and in n
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release
Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso
Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 15:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 14:12:00 EEST | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critical infrastructure required to support housing and industrial growth across North West England, as well as playing a crucial role in supporting nationally important initiatives related to AI data centres and sustainable energy. ATLAS strongly supports UU’s decision to raise new equity in order to accelerate its investment program through providing significant balance sheet capacity and financial flexibility through to the end of AMP8 in 2030. ATLAS values th
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 13:37:00 EEST | Press release
Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent. With extensive senior leadership experience across top-tier life-sciences investment funds, pharma and Biopharma companies, Elaine Caughey and Sarah Shackelton bring deep expertise in life sciences operations, investment, recruitment, and team building. Their appointments are synergistic and aligned with Jeito’s strategy, combining complementary skills across the full drug value chain to support portfolio company development and advance breakthrough therapies for patients. Building on a series of recent high-profile hires — including Samit Hirawat, M.D. as Strategic Medical Advisor, bringing senior leadership and clinical development experience at Novartis and Bristol Myers Squibb; Karin Van Baelen as Chief Regulatory Advisor, with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
